Chelator based non-metallic radionuclide drug conjugate, precursors thereof and their applications

WO2026124580A1PCT designated stage Publication Date: 2026-06-18HANGZHOU SAIHE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
HANGZHOU SAIHE BIOTECHNOLOGY CO LTD
Filing Date
2025-12-11
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current methods for coupling non-metallic radionuclides with targeting ligands are inefficient, complex, and toxic, limiting the development of therapeutic and diagnostic radionuclide-drug conjugates (RDCs) for precision medicine.

⚗Method used

A non-metallic radionuclide drug conjugate structure (LG) m-(S) o-(L) p-C-R) is developed, where LG is a targeting ligand, S is a spacer, L is a linker, C is a chelator with metal atoms/ions, and R is a non-metallic radionuclide like iodine or astatine, connected via coordination bonds, using a novel reverse chelation process with metal ions forming a cage-like structure for enhanced binding.

🎯Benefits of technology

The novel conjugate enables efficient, stable, and rapid coupling of non-metallic radionuclides to targeting molecules, reducing toxicity and facilitating clinical application with improved tumor uptake and reduced off-target effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2025141730_18062026_PF_FP_ABST
    Figure CN2025141730_18062026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a non-metallic radionuclide drug conjugate and a precursor thereof, a pharmaceutical composition based on the drug conjugate or a precursor thereof, as well as the use thereof the same in the field of disease prevention and / or treatment. Specifically, the non-metallic radionuclide drug conjugate comprises a targeting ligand, an optional spacer and a linker, a chelator comprising one or more metal atoms / ions, and a non-metallic radionuclide selected from iodine, astatine or fluorine connected to the chelator via one or more chemical bonds. The present invention also provides a separate administration of the conjugate precursor and the radionuclide, which can be conjugated together in vivo.
Need to check novelty before this filing date? Find Prior Art